Drug Trial Radar · NCT06824194
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,360
Actual
Start
Feb 18, 2025
Primary completion
Oct 22, 2027
Study completion Oct 22, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 89 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.
Conditions
- Pneumococcal Immunization
Interventions
PCV21 vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Prevnar 20 vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
M-M-R II vaccineBiological
Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
RotarixBiological
Pharmaceutical form:Solution-Route of administration:Oral
RotaTeqBiological
Pharmaceutical form:Solution-Route of administration:Oral
Vaxelis vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
VarivaxBiological
Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
PriorixBiological
Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous
VAQTABiological
Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
HavrixBiological
Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of any immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
- Presence of solicited injection site and systemic reactions through 7 days after each vaccine injectionTime frame: Through 7 days after each vaccine injection
- Presence of unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs through 30 days after each vaccine injectionTime frame: Through 30 days after each vaccine injection
- Presence of serious adverse events (SAEs) throughout the study (through 6 months post- last vaccine injection)Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months
- Presence adverse events of special interest (AESIs) throughout the study (through 6 months post- last vaccine injection)Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months
Locations
132 sites in 6 countries. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400013
Birmingham, Alabama
University of Alabama at Birmingham- Site Number : 8400130
Birmingham, Alabama
Lakeview Clinical Research- Site Number : 8400054
Guntersville, Alabama
Midway Medical Clinic- Site Number : 8400091
Oneonta, Alabama
Noble Clinical Research- Site Number : 8400121
Tucson, Arizona
The Children's Clinic- Site Number : 8400079
Jonesboro, Arkansas
Helios CR, Inc. - Little Rock- Site Number : 8400090
Sherwood, Arkansas
Helping Hands Healthcare Group - Fullerton- Site Number : 8400063
Fullerton, California
Advanced Investigative Medicine- Site Number : 8400055
Hawthorne, California
Century Research Institute- Site Number : 8400118
Huntington Park, California
Matrix Clinical Research - Huntington Park- Site Number : 8400117
Huntington Park, California
Matrix Clinical Research - Los Angeles- Site Number : 8400026
Los Angeles, California
Matrix Clinical Research - Los Angeles- Site Number : 8400123
Los Angeles, California
Alliance Research Institute - Lynwood- Site Number : 8400099
Lynwood, California
Madera Family Medical Group- Site Number : 8400011
Madera, California
FOMAT-Golden Valley Health Centers- Site Number : 8400084
Merced, California
Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400072
Palo Alto, California
Center for Clinical Trials - Paramount- Site Number : 8400100
Paramount, California
Integrated Clinical Research LLC- Site Number : 8400027
Sherman Oaks, California
Emanate Health - Queen of the Valley Hospital- Site Number : 8400105
West Covina, California
All In One Clinic- Site Number : 8400127
Whittier, California
Amicis Research Center-Winnetka- Site Number : 8400128
Winnetka, California
Emerson Clinical Research Institute - Washington - Connecticut Avenue- Site Number : 8400102
Washington D.C., District of Columbia
D&H Doral Research Center- Site Number : 8400095
Doral, Florida
Dolphin Medical Research, LLC- Site Number : 8400120
Doral, Florida
Nextlevel Research Center- Site Number : 8400065
Doral, Florida
CuraCare- Site Number : 8400125
Kendall, Florida
PAS RESEARCH-Lutz- Site Number : 8400103
Lutz, Florida
Abba Medical Research- Site Number : 8400064
Miami, Florida
D&H National Research Center- Site Number : 8400085
North Miami, Florida
Alfa Medical Research LLC- Site Number : 8400111
Pembroke Pines, Florida
PAS Research - Tampa- Site Number : 8400113
Tampa, Florida
Morehouse School of Medicine - Atlanta- Site Number : 8400093
Atlanta, Georgia
CenExel - iResearch - Savannah- Site Number : 8400057
Savannah, Georgia
Bingham Memorial Hospital - Blackfoot- Site Number : 8400114
Blackfoot, Idaho
Elite Clinical Trials - Blackfoot- Site Number : 8400017
Blackfoot, Idaho
Clinical Research Prime- Site Number : 8400022
Idaho Falls, Idaho
Eagle Clinical Research- Site Number : 8400087
Chicago, Illinois
University of Chicago Medical Center- Site Number : 8400062
Chicago, Illinois
MidValley Research - Moline- Site Number : 8400096
Moline, Illinois
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.